Is ticagrelor worth its high cost and side-effects?

Guerbaai, Raphaëlle-Ashley and Mahata, Indrajeet and Maréchaux, Sylvestre and Le Jemtel, Thierry H. and Ennezat, Pierre-Vladimir. (2019) Is ticagrelor worth its high cost and side-effects? Acta cardiologica, 74 (2). pp. 93-98.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/76771/

Downloads: Statistics Overview


Ticagrelor is a reversible P2Y; 12; receptor antagonist that is more potent than clopidogrel. When used in combination with aspirin, it reduces cardiovascular events in patients with acute coronary syndrome. However, unbiased review of 5 randomised controlled trials indicates that although statistically significant, the clinical superiority of ticagrelor over clopidogrel is modest. Thus, identification of patients who benefit the most from ticagrelor is a priority. Besides bleeding issues, ticagrelor can frequently cause bouts of dyspnoea, which requires ticagrelor replacement by another P2Y; 12; receptor antagonist, with a loading dose.
Faculties and Departments:03 Faculty of Medicine > Departement Public Health > Institut für Pflegewissenschaft
UniBasel Contributors:Guerbaai, Raphaelle Ashley
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Taylor & Francis
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:06 Jul 2020 14:44
Deposited On:22 Jun 2020 12:41

Repository Staff Only: item control page